Teguh Aryandono

Teguh Aryandono

Auto-generated profile, based on publicly available information

Teguh Aryandono

Division of Oncology Surgery, Department of Surgery, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta 55281, Indonesia

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Archives of Plastic Surgery
Verified
Journal Article
Open access
PDF file
IRIrena Sakura Rini
Irena Sakura Rini
AGAlberta Jesslyn Gunardi
Alberta Jesslyn Gunardi
RMRenate Parlene Marsaulina
Renate Parlene Marsaulina
TATeguh Aryandono
Teguh Aryandono
IDIshandono Dachlan
Ishandono Dachlan
IDIwan Dwiprahasto
Iwan Dwiprahasto
The keystone design perforator island flap can be utilized in the repair of trunk defects. A systematic review was carried out to identify the complication rates of the use of this flap to treat such defects. The MEDLINE, Embase, Cochrane Library, and PubMed Central databases were searched for articles published between January 2003 and December 2018 that reported the use of keystone design perforator island flaps in the repair of trunk defects. Study selection was conducted in alignment with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Eight articles involving a total of 54 flaps satisfied the inclusion criteria. The most frequently reported cause of trunk defects was oncologic resection (64.4%). The overall complication rate was 35.2%, and complications included infection (11.1%), wound dehiscence (7.4%), delayed healing (7.4%), and partial flap loss (1.9%). The keystone design perforator island flap is associated with a high success rate and low technical complexity. Despite minor complications, keystone design flaps could be a preferred choice for trunk reconstruction.

1 January 2021 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
KTKartika Widayati Taroeno-Hariadi
Kartika Widayati Taroeno-Hariadi
YPYasjudan Rastrama Putra
Yasjudan Rastrama Putra
LCLina Choridah
Lina Choridah
IWIrianiwati Widodo
Irianiwati Widodo
MHmardiah suci hardianti
mardiah suci hardianti
TATeguh Aryandono
Teguh Aryandono
Taroeno-Hariadi KW, et al. J Breast Cancer. 2021 Sep;24:e41. https://doi.org/10.4048/jbc.2021.24.e41

1 January 2006 in Biotechnic & Histochemistry
Verified
Journal Article
Closed access
DPD Purnomosari
D Purnomosari
TAT Aryandono
T Aryandono
KSK Setiaji
K Setiaji
SNSb Nugraha
Sb Nugraha
GPGerard Pals
Gerard Pals
PDPj van Diest
Pj van Diest
The HER-2/neu transmembrane tyrosine kinase receptor is both a prognostic marker and a therapeutic target for breast cancer. Accurate determination of HER-2/neu status is a prerequisite for selecting breast tumors for HER-2/neu immunotherapy or for taxan based chemotherapy. Unfortunately, there is no consensus concerning how this determination should be reached. We compared assessment of HER-2/neu status using Multiplex ligation-dependent probe amplification (MLPA) and immunohistochemistry (IHC). The patient group comprised 60 Indonesian breast cancers patients. IHC was performed on paraffin sections using the CB11 antibody from Novocastra. Results were scored according to the Hercept test. For MLPA, DNA was extracted from frozen samples, PCR amplified with a probe set containing three hemi-primer sets for the HER-2 locus and another nine control probes spread over chromosome 17 and other chromosomes, and analyzed on a gene scanner. A ratio above two for at least two HER-2 locus probes compared to the control probes was regarded as amplification. IHC for HER-2/neu was negative in 36 cases, and 24 cases (40%) showed expression. Seven, eight and nine of the latter cases were 1+, 2+ and 3+ positive, respectively. Forty-seven cases showed no amplification by MLPA, and 13 cases (22%) were amplified. Comparison of IHC and MPLA showed that none of the 36 IHC-negative or seven IHC 1+ cases was amplified. Five of the eight (63%) 2+ cases were amplified, and eight of nine (89%) of the IHC 3+ tumors showed gene amplification by MLPA assay. For HER-2/neu, there is a good correlation between gene amplification detected by MLPA and overexpression by IHC in invasive breast cancer. It appears that MLPA can detect the HER-2 amplified cases in the IHC 2+ class. Because MLPA is quick and inexpensive, it is an attractive method for detecting HER-2/neu amplification in daily laboratory practice.

1 September 2022 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
KTKartika Widayati Taroeno-Hariadi
Kartika Widayati Taroeno-Hariadi
YPYasjudan R Putra
Yasjudan R Putra
NANina F Ariesta
Nina F Ariesta
HSHemi Sinorita
Hemi Sinorita
MHmardiah suci hardianti
mardiah suci hardianti
TATeguh Aryandono
Teguh Aryandono
Background: Obesity and metabolic syndrome (MetS) have been linked to the risk of developing certain cancers. This study aimed to analyze the association between obesity markers, MetS and survival outcomes of patients with breast cancer. Methods: This study retrospectively investigated patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-), nonmetastatic breast cancer diagnosed between January 2010 and December 2019. Data on clinical conditions, body mass index (BMI), waist-to-hip ratio (WHR), MetS, time of metastasis and death were collected. Results: A total of 223 breast cancer patient records were eligible for analysis. Obesity (BMI ≥ 25) was found in 38.1% of cases. Abdominal obesity measured as WHR ≥ 0.85 was found in 48.9%. Metabolic syndrome was detected in 56.1% of patients and was associated with older age (OR = 2.196, p = 0.005), postmenopausal status (OR = 2.585, p = 0.001), obesity (OR = 5.684, p = 0.001) and abdominal obesity (OR = 2.612, p = 0.001). Obesity was not associated with poor disease-free survival (DFS) or overall survival (OS), while abdominal obesity was modestly associated with poor DFS (HR = 1.539, p = 0.083) and OS (HR = 3.117; p = 0.019). Multivariate analysis revealed that WHR ≥ 0.85 was independently associated with unfavorable DFS (HR = 1.907, p = 0.027). Patients with MetS had a similar survival rate to those with normal metabolism. Conclusion: In Indonesian women with HR+/HER2- breast cancers, obesity and MetS were not associated with poor survival outcomes. The abdominal obesity marker (WHR) was more accurate in predicting unfavorable DFS.

4 October 2025 in Burns
Verified
Journal Article
Closed access
MSMuhammad Rosadi Seswandhana
Muhammad Rosadi Seswandhana
HHHamim Majdy Awliya Humani
Hamim Majdy Awliya Humani
GGGita Christy Gabriela
Gita Christy Gabriela
IDIshandono Dachlan
Ishandono Dachlan
ELEstelita Liana
Estelita Liana
IWIrianiwati Widodo
Irianiwati Widodo

1 January 2020 in Journal of Cancer Research and Practice
Verified
Journal Article
Open access
PDF file
TCTsu- Yi Chao
Tsu- Yi Chao
PSPamungkas Bagus Satriyo
Pamungkas Bagus Satriyo
Chi-Tai YehChi-Tai Yeh
Chi-Tai Yeh
JCJia-Hong Chen
Jia-Hong Chen
TATeguh Aryandono
Teguh Aryandono
SHSofia Mubarika Haryana
Sofia Mubarika Haryana
Objective: Triple-negative breast cancer (TNBC) is characterized by a lack of estrogen receptors (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu). Only 30% of TNBC patients show a pathologic complete response, and the other 70% of patients exhibit a less pronounced response followed by relapse and metastasis to distant organs after neoadjuvant chemotherapy. Achievements of immunotherapy targeting programmed cell death 1 ligand 1 (PD-L1) in clinical trials for treating melanoma, nonsmall-cell lung cancer, renal cell carcinoma, and TNBC suggest that targeting the interaction of tumor cells with tumor microenvironment is highly beneficial for cancer treatment. Finding a novel dual-targeting therapy against tumor cells and the tumor microenvironment (TME) may provide options for improved responses in TNBC patients. Data Sources: We searched the potential targeted therapy candidates that regulate tumor cells as well as the TME of cancer diseases, including TNBC, based on our previous and recent other publications. Study Selection: We selected the potential targeted therapies supported by relevance clinical data, in vitro and in vivo studies. Results: In this review, we found the KDM5B, Cadherin 11, β-catenin, CDK2, signal peptide CUB-EGF domain-containing protein 2, and PDL1 regulate the tumor cells and TME of TNBC cells. In addition, we also highlighted the Antrocin, Ovatodiolide, and Pterostilbene as natural small compound possess anti-cancer through the disruption of tumor cell–TME interactions. Conclusion: The new therapy approach targeting tumor cells-TME interaction may improve the response and survival rate of TNBC patients. Later, natural small compounds could provide alternative therapy options for TNBC patients.